Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cells, such as regulatory T cells (Tregs), in the tumor microenvironment (TME) play an important role in the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC).
Methods: The densities of TILs, programmed death receptor 1 (PD-1) + T cells, and forkhead box P3 (Foxp3) + T cells were analyzed by immunohistochemical staining. The associations of the immunological status of the PDAC microenvironment with overall survival (OS) time and disease-free survival (DFS) time were evaluated.
Results: PDAC patients with a high density of TILs in the TME or PD-1-positive T cells in tertiary lymphoid aggregates (TLAs) demonstrated a significantly better prognosis than those with a low density of TILs or PD-1-negativity, respectively. Moreover, PDAC patients with high levels of Foxp3-expressing T cells showed a worse prognosis than those with low levels of Foxp3-expressing T cells. Importantly, even with a high density of the TILs in TME or PD-1-positive T cells in TLAs, PDAC patients with high levels of Foxp3-expressing T cells showed a worse prognosis than patients with low levels of Foxp3-expressing T cells. A PDAC TME with a high density of TILs/high PD-1 positivity/low Foxp3 expression was an independent predictive marker associated with superior prognosis.
Conclusion: Combined assessment of TILs, PD-1+ cells, and Foxp3+ T cells in the TME may predict the prognosis of PDAC patients following surgical resection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582170 | PMC |
| http://dx.doi.org/10.1186/s12885-021-08911-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.
Pancreatology
August 2025
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, remains a therapeutic challenge. While GALNT4 (a member of the N-acetylgalactosaminyltransferases family) shows significant upregulation in PDAC cells, its precise oncogenic mechanisms remain poorly understood.
Methods: Bioinformatics analysis was performed to examine the expression of GALNT4 and MUC1 in pancreatic adenocarcinoma (PAAD) and to predict the glycosylation sites of MUC1.
Background: This systematic review and meta-analysis compared the intraoperative and postoperative outcomes of minimally invasive versus open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC), which is a highly aggressive tumor with a high mortality rate. Surgical resection remains the only potentially curative treatment. Minimally invasive distal pancreatectomy (MIDP), including laparoscopic and robotic approaches, has gained popularity, although the evidence of its efficacy is limited.
View Article and Find Full Text PDFNuclear cGAS mediated Replication Stress and Mitotic Catastrophe can Overcome Gemcitabine Resistance.
Cancer Lett
September 2025
Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA; Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR, USA.
Gemcitabine, a ribonucleotide reductase (RNR) inhibitor, is active in pancreatic ductal carcinoma (PDAC) patients, but unfortunately has a limited impact on long term outcomes. Gemcitabine induces nucleotide deficiency, DNA damage including single stranded DNA (ssDNA) and replication stress (RS). DNA damage can activate cyclic GMP-AMP synthase (cGAS), leading to genome instability, micronucleus generation, and immune activation.
View Article and Find Full Text PDFRisk Factors in Predicting Radiologically Occult Metastatic Disease from Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience with Routine Preoperative Magnetic Resonance Imaging.
J Gastrointest Surg
September 2025
Department of Surgery, Mayo Clinic, Jacksonville, Florida. Electronic address:
Background: Limited data exists regarding the incidence of aborted pancreatic surgery due to radiologically occult metastatic disease (ROMD). This study presents a single-institution experience aimed at identifying potential risk factors associated with ROMD of patients undergoing routine preoperative magnetic resonance imaging with pancreatic ductal adenocarcinoma (PDAC) METHODS: Patients with PDAC taken for curative intent pancreatic surgery between January 2012 and December 2022 following preoperative imaging MRI protocol were retrospectively reviewed, and those who had aborted surgery due to ROMD were identified. Binary logistic regression analysis was performed to identify potential predictors of ROMD.
View Article and Find Full Text PDFTumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer.
Semin Oncol
September 2025
Departments of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, New Jersey, USA. Electronic address:
Chimeric antigen receptor (CAR) T-cell therapy has changed how we treat blood cancers but hasn't worked as well for solid tumors like pancreatic ductal adenocarcinoma (PDAC), mainly because these tumors are very aggressive and resistant to regular treatments. This review critically examines peer-reviewed studies to chart the evolution of immunotherapy in PDAC, emphasizing the unique barriers to effective CAR T-cell treatment and emerging strategies to overcome them. CAR T-cells that focus on tumor-related markers like mesothelin, HER2, and MUC1 have shown promise in early research models.
View Article and Find Full Text PDF